Venom Evolution Lab, School of Biological Science, University of Queensland, St. Lucia, QLD, Australia.
Department of Biochemistry & Microbiology, North South University, Dhaka, Bangladesh.
Front Immunol. 2021 Jun 10;12:688802. doi: 10.3389/fimmu.2021.688802. eCollection 2021.
Palearctic vipers are medically significant snakes in the genera , and which occur throughout Europe, Central Asia, Near and Middle East. While the ancestral condition is that of a small-bodied, lowland species, extensive diversification has occurred in body size, and niche specialization. Using 27 venom samples and a panel of coagulation assays, we evaluated the relative coagulotoxic potency of Palearctic viper venoms and compared their neutralization by three antivenoms (Insoserp Europe, VIPERFAV and ViperaTAb) and two metalloprotease inhibitors (prinomastat and DMPS). We show that variation in morphology parallels variation in the Factor X activating procoagulant toxicity, with the three convergent evolutions of larger body sizes ( genus, genus, and uniquely within the genus) were each accompanied by a significant increase in procoagulant potency. In contrast, the two convergent evolutions of high altitude specialization (the genus and uniquely within the genus) were each accompanied by a shift away from procoagulant action, with the species being particularly potently anticoagulant. Inoserp Europe and VIPERFAV antivenoms were both effective against a broad range of species, with Inoserp able to neutralize additional species relative to VIPERFAV, reflective of its more complex antivenom immunization mixture. In contrast, ViperaTAb was extremely potent in neutralizing but, reflective of this being a monovalent antivenom, it was not effective against other species. The enzyme inhibitor prinomastat efficiently neutralized the metalloprotease-driven Factor X activation of the procoagulant venoms. In contrast, DMPS (2,3-dimercapto-1-propanesulfonic acid), which as been suggested as another potential treatment option in the absence of antivenom, DMPS failed against all venoms tested. Overall, our results highlight the evolutionary variations within Palearctic vipers and help to inform clinical management of viper envenomation.
古北界蝰蛇是属和属中的医学上重要的蛇类,分布于整个欧洲、中亚、近东和中东。虽然祖先的情况是体型小、生活在低地的物种,但在体型和生态位特化方面已经发生了广泛的多样化。我们使用 27 个毒液样本和一组凝血测定,评估了古北界蝰蛇毒液的相对凝血毒性,并比较了三种抗蛇毒血清(Insoserp Europe、VIPERFAV 和 ViperaTAb)和两种金属蛋白酶抑制剂(普林玛司他和 DMPS)对其的中和作用。我们表明,形态的变异与因子 X 激活促凝血毒性的变异平行,三个体型较大的趋同进化(属、属和属中独特的进化)都伴随着促凝血毒性的显著增加。相比之下,两个高海拔特化的趋同进化(属和属中独特的进化)都伴随着促凝血作用的转移,而 种则具有特别强的抗凝作用。Insoserp Europe 和 VIPERFAV 抗蛇毒血清对广泛的 种都有效,Insoserp 相对于 VIPERFAV 能够中和更多的种,反映了其更复杂的抗蛇毒血清免疫混合物。相比之下,ViperaTAb 对 种非常有效,但由于它是一种单价抗蛇毒血清,对其他 种无效。酶抑制剂普林玛司他有效地中和了促凝血毒液中金属蛋白酶驱动的因子 X 激活。相比之下,DMPS(2,3-二巯基-1-丙磺酸),作为一种在没有抗蛇毒血清的情况下的另一种潜在治疗选择,在所有测试的毒液中都失败了。总的来说,我们的结果突出了古北界蝰蛇的进化变异,并有助于为毒蛇咬伤的临床管理提供信息。